The Current State of Targeted Agents in Rectal Cancer

Abstract EN

Targeted biologic agents have an established role in treating metastatic colorectal cancer (CRC), and the integration of targeted therapies into the treatment of CRC has resulted in significant improvements in outcomes.

Rapidly growing insight into the molecular biology of CRC, as well as recent developments in gene sequencing and molecular diagnostics, has led to high expectations for the identification of molecular markers to be used in personalized treatment regimens.

The mechanisms of action and toxicities of targeted therapies differ from those of traditional cytotoxic chemotherapy.

Targeted therapy has raised new insight about the possibility of tailoring treatment to an individual’s disease, the assessment of drug effectiveness and toxicity, and the economics of cancer care.

This paper covers the last decade of clinical trials that have explored the toxicity and efficacy of targeted agents in locally advanced and metastatic CRC and how their role may benefit patients with rectal cancer.

Future efforts should include prospective studies of these agents in biomarker-defined subpopulations, as well as studies of novel agents that target angiogenesis, tumor-stromal interaction, and the cell signaling pathways implicated in rectal cancer.